Quick answer: what is IGF-1 DES?
IGF-1 DES (DES(1-3)IGF-1) is a shortened, more potent variant of insulin-like growth factor 1, marketed for muscle growth.
Quick facts
- Class
- Truncated IGF-1 analog
- Related to
- IGF-1 and IGF-1 LR3
- Studied for
- Tissue and muscle growth (animal / cell models)
- Evidence level
- Preclinical; no human performance trials
- Approval
- Not FDA-approved; sold as a research chemical
- Structure
- IGF-1 lacking first 3 amino acids
- Related compound
- IGF-1 LR3
- Human evidence
- None (animal / cell studies only)
Key takeaways
- Missing its first three amino acids, it escapes the binding proteins that normally restrain IGF-1, leaving more of it free to act.
- It is studied only in animals and cells; there are no human trials for muscle building or performance.
- It is not FDA-approved, is sold as a research chemical, and IGF-1 analogs are banned in sport.
Overview
IGF-1 DES, more precisely DES(1-3)IGF-1, is a naturally occurring variant of insulin-like growth factor 1 that is missing the first three amino acids of the normal molecule. That small truncation has an outsized effect: it makes the peptide substantially more potent in tissue.[3]
It sits alongside IGF-1 LR3 as one of the modified IGF-1 forms circulated in bodybuilding for muscle growth. Like LR3, it is a research chemical with no approved use and no human performance evidence.
How it works
Normal IGF-1 is largely held in check by IGF-binding proteins that limit how much is free to act. Removing the first three amino acids sharply reduces DES(1-3)IGF-1's affinity for these binding proteins, leaving more of it free to activate the IGF-1 receptor.[3] Through that receptor it stimulates the Akt and downstream growth pathways that drive cell proliferation and protein synthesis in muscle and other tissues.[4]
Because it evades the binding-protein brake, it is reported to be several-fold more potent than standard IGF-1 in laboratory settings.
Research & evidence
The evidence is entirely preclinical. In animal studies, DES(1-3)IGF-1 enhanced growth in models of tissue repair — for example after gut resection or in rats with reduced kidney mass — often more potently than intact IGF-1.[1][2] Cell studies show it activates the growth-signaling machinery of skeletal muscle.[4]
None of this has been tested as a muscle-building or performance therapy in humans. Claims of localized muscle growth are extrapolated from animal potency data, not from controlled human trials, which do not exist.
Safety & legal status
Human safety data are absent. The theoretical concerns that apply to any potent IGF-1 signal — including effects on blood sugar and the general worry that strongly driving growth pathways could promote abnormal cell growth — mean its risk profile is genuinely unknown. Unregulated products also carry purity and sterility risks. IGF-1 DES is not FDA-approved, is sold only as a research chemical, and IGF-1 analogs are banned in sport by WADA.
Frequently asked questions
What is IGF-1 DES?
IGF-1 DES, or DES(1-3)IGF-1, is a naturally occurring variant of insulin-like growth factor 1 that is missing the first three amino acids. This makes it evade IGF-binding proteins and act more potently in tissue, which is why it is circulated in bodybuilding for muscle growth.
How is IGF-1 DES different from IGF-1 LR3?
Both are modified IGF-1 forms designed to evade binding proteins and act more potently and, for LR3, more durably. IGF-1 DES is a truncated version (missing three amino acids), while LR3 is a lengthened, substituted version. Neither has human performance evidence.
Does IGF-1 DES build muscle?
In animal and cell studies it potently activates muscle growth pathways, but there are no controlled human trials showing it builds muscle or improves performance. Claims of localized muscle growth are extrapolated from animal data, not demonstrated in people.
Is IGF-1 DES safe or legal?
Its human safety is unknown, and strongly driving IGF-1 growth signaling carries theoretical risks including effects on blood sugar and abnormal cell growth. It is not FDA-approved, is sold only as a research chemical, and IGF-1 analogs are banned in sport by WADA.
References
Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.
- Martin AA, Tomas FM, Owens PC, et al. IGF-I and its variant, des-(1-3)IGF-I, enhance growth in rats with reduced renal mass. Am J Physiol. 1991. Peer-reviewed study
- Lemmey AB, Martin AA, Read LC, et al. IGF-I and the truncated analogue des-(1-3)IGF-I enhance growth in rats after gut resection. Am J Physiol. 1991. Peer-reviewed study
- Ballard FJ, Wallace JC, Francis GL, et al. Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol. 1996. Peer-reviewed study
- Li M, Li C, Parkhouse WS. Age-related differences in the des IGF-I-mediated activation of Akt-1 and p70 S6K in mouse skeletal muscle. Mech Ageing Dev. 2003. Peer-reviewed study